Weekly Incretin Analog Dose Escalation for GI Tolerability

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for type 2 diabetes mellitus (T2DM) and obesity-related conditions using GCG, GLP-1, and GIP triple receptor agonists face challenges with gastrointestinal adverse events and require multiple weeks to reach steady state activity, limiting efficacy and patient compliance.

Innovation Solution

Optimized doses and dosing regimens for a GGG tri-receptor agonist (SEQ ID NO:1) ranging from 0.5 mg to 12.0 mg, administered weekly with incremental adjustments, to provide effective glycemic control and weight management while minimizing adverse events.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If high doses of GGG tri-receptor agonist are administered to achieve effective glycemic control and weight management, then therapeutic efficacy is improved, but gastrointestinal adverse events increase

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidgastrointestinal adverse events

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent divides the total treatment dose into multiple smaller doses administered at different time points (e.g., 0.5mg, 1.0mg, 2.0mg, 3.0mg, 4.0mg, 6.0mg, 8.0mg, 10.0mg, 12.0mg in sequential weeks). This segmentation allows the body to gradually adapt to the incretin agonist, reducing gastrointestinal adverse events while ultimately achieving the target therapeutic dose for effective glycemic control and weight management.

Inventive Principle:

Principle #1Segmentation

2Ease of operation

If once-weekly dosing is used to reduce injection frequency and improve compliance, then ease of operation is improved, but time to reach steady state activity increases

Engineering Contradiction:

Improveinjection frequencyVSAvoidtime to reach steady state

Core Design Contradiction:

Ease of operationVSLoss of time

Solution Approach 1:

The patent implements a preliminary dose escalation phase where the dose is increased gradually over the first several weeks (from 0.5mg up to the target maintenance dose). This preliminary action allows the body to adapt to the drug before full therapeutic dosing begins, enabling faster achievement of steady state once the maintenance dose is reached, while maintaining the convenient once-weekly administration schedule.

Inventive Principle:

Principle #10Preliminary action

3Object-affected harmful factors

If dose escalation is implemented to minimize adverse events, then tolerability is improved, but treatment duration to reach effective dose increases

Engineering Contradiction:

Improveadverse events profileVSAvoidtime to reach effective dose

Core Design Contradiction:

Object-affected harmful factorsVSLoss of time

Solution Approach 1:

The patent employs a dynamic dosing regimen where the weekly dose is adjusted based on patient tolerance and response. The dose escalation schedule (0.5mg, 1.0mg, 2.0mg, 3.0mg, 4.0mg, 6.0mg, 8.0mg, 10.0mg, 12.0mg) allows flexible progression through dose levels, enabling patients to reach the effective therapeutic dose more quickly once tolerance is established, while maintaining an optimized adverse events profile throughout the treatment course.

Inventive Principle:

Principle #15Dynamics

Data Source

PatentUS20260091088A1Methods of using and compositions including an incretin analog

Publication Date: 2026.04.02 ELI LILLY & CO

AI summary

Doses and dosing regimens for incretin analogs are disclosed comprising determining and administering doses of long-acting incretin analogs suitable for once-weekly dosing, such as a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) (GGG) tri-receptor agonist.